Latest Idera Pharmaceuticals Inc. Stories
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in patients with metastatic or recurrent clear cell renal carcinoma (RCC). The primary objective was not achieved in the study.
Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLRs), today announced the formation of an Autoimmune Disease Scientific Advisory Board.
- An imitative word; an onomatopoetic word.